The Myocarditis drugs in development market research report provides comprehensive information on the therapeutics under development for Myocarditis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Myocarditis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Myocarditis and features dormant and discontinued products.

GlobalData tracks 11 drugs in development for Myocarditis by 11 companies/universities/institutes. The top development phase for Myocarditis is preclinical with five drugs in that stage. The Myocarditis pipeline has ten drugs in development by companies and one by universities/ institutes. Some of the companies in the Myocarditis pipeline products market are: Cantargia, Swedish Orphan Biovitrum and Bristol-Myers Squibb.

The key targets in the Myocarditis pipeline products market include T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86), T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80), and Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1).

The key mechanisms of action in the Myocarditis pipeline product include Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) Agonist with one drug in Phase II. The Myocarditis pipeline products include seven routes of administration with the top ROA being Subcutaneous and seven key molecule types in the Myocarditis pipeline products market including Monoclonal Antibody, and Small Molecule.

Myocarditis overview

Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain; rapid or abnormal heartbeat; shortness of breath, at rest or during physical activity; fluid retention with swelling of the legs, ankles, and feet; and fatigue. Treatment includes antibiotics, anti-inflammatory medicines to reduce swelling; and diuretics to remove excess water from the body.

For a complete picture of Myocarditis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.